Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report

The New England Journal of Medicine
October 2017

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

The Journal of Infectious Diseases
March 2019

Filter by Category

HPV-Targeted

Immuno-Oncology (Non HPV-Associated)

Infectious Diseases (Non HPV-Associated)

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Other Development Candidates

Delivery Technology/Proprietary Smart Device

HPV-Targeted

Title	Disease Target	Product
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Science Translational Medicine — October 2012	Disease TargetCervical Dysplasia	ProductVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100 Molecular Therapy Oncolytics — January 2016	Disease TargetCervical Dysplasia	ProductVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy Clinical Cancer Research — January 2018	Disease TargetCervical Dysplasia	ProductVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis BMJ — July 2016	Disease TargetCervical Dysplasia	ProductVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis Vaccines — January 2020	Disease TargetRRP	ProductINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer Clinical Cancer Research — January 2019	Disease TargetHead & Neck Cancer	ProductMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial The Lancet — September 2015	Disease TargetCervical Dysplasia	ProductVGX-3100

Immuno-Oncology (Non HPV-Associated)

Title	Disease Target	Product
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017	Disease TargethTERT	ProductINO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013	Disease TargethTERT	ProductINO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017	Disease TargetWT1	ProductINO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020	Disease TargetPSA	ProductINO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011	Disease TargetPSA, PSMA	ProductINO-5401

Infectious Diseases (Non HPV-Associated)

Title	Disease Target	Product
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals Molecular Therapy — March 2015	Disease TargetHIV	ProductPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo PLoS ONE — December 2013	Disease TargetHIV	ProductPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine Vaccine — September 2011	Disease TargetHIV	ProductPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers The Journal of Infectious Diseases — March 2019	Disease TargetEbola	ProductINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines The Journal of Infectious Diseases — October 2018	Disease TargetEbola	ProductINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus Microbes and Infection — December 2018	Disease TargetZika	ProductINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization The Journal of Infectious Diseases — July 2018	Disease TargetZika	ProductINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes Nature Communications — June 2017	Disease TargetZika	ProductINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine npj Vaccines — November 2016	Disease TargetZika	ProductINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates Science Translational Medicine — August 2015	Disease TargetMERS	ProductINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine Vaccine — May 2018	Disease TargetInfluenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model Nature Communications — September 2017	Disease TargetPseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus The Journal of Infectious Diseases — March 2016	Disease TargetChikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy Scientific Reports — July 2015	Disease TargetDengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses Journal of Hepatology — February 2020	Disease TargetHepatitis C	ProductGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial The Lancet Infectious Diseases — July 2019	Disease TargetMERS	ProductINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report The New England Journal of Medicine — October 2017	Disease TargetZika	ProductINO-4600
Immunogenicity of a DNA vaccine candidate for COVID-19 Nature Communications — May 2020	Disease TargetCOVID-19	ProductINO-4800

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Title	Disease Target	Product
Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge Human Vaccines & Immunotherapeutics — December 2019	Disease TargetZika	ProductINO-A002
In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus Molecular Therapy — April 2019	Disease TargetZika	ProductINO-A002
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model Cell Reports — November 2018	Disease TargetEbola
Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo Cancer Research — November 2018	Disease TargetCTLA-4
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody Cancer Immunology, Immunotherapy — August 2017	Disease TargetProstate Cancer
DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections npj Vaccines — July 2017	Disease TargetInfluenza

Other Development Candidates

Title	Disease Target	Product
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight — April 2019	Disease TargetHER2

Delivery Technology/Proprietary Smart Device

Title	Disease Target	Product
Electroporation delivery of DNA vaccines: prospects for success Current Opinion in Immunology — June 2011	Disease TargetDelivery	ProductCELLECTRA^®
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011	Disease TargetDelivery	ProductCELLECTRA
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019	Disease TargetDelivery	ProductCELLECTRA

© Copyright 2020 INOVIO Pharmaceuticals. All rights reserved.